Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial
在既往未接受过内分泌治疗的激素受体阳性、HER2阴性晚期乳腺癌患者中，瑞博西尼联合来曲唑治疗：来自3b期CompLEEment-1试验的亚组安全性分析
期刊:Radiology and Oncology
影响因子:2.2
doi:10.2478/raon-2022-0020
Borstnar, Simona; Palacova, Marketa; Łacko, Aleksandra; Timcheva, Constanta; Gal-Yam, Einav Nili; Papazisis, Konstantinos; Beniak, Juraj; Kudela, Pavol; Rubovszky, Gábor
